VENUS: Ustekinumab Superior to Vedolizumab for Refractory Crohn’s
In a first insist comparability look, ustekinumab (Stelara, Janssen) emerged superior to vedolizumab (Entyvio, Takeda) on more than one measures of response and remission among patients with Crohn’s illness who failed at the least one anti-TNF therapy.
Of patients taking ustekinumab, a increased percentage (51%) met the predominant endpoint of corticosteroid-free clinical remission at week 54. Within the vedolizumab team, handiest 41% achieved the identical .
“Failure to anti-TNF therapy is a predominant project in Crohn’s illness,” Anthony Buisson, MD, PhD, head of the Inflammatory Bowel Disease Unit, College Clinic Estaing, Clermont-Ferrand, France, stated at some level of the Digestive Disease Week (DDW) 2021 digital assembly.
Buisson estimated that 15% of patients with Crohn’s illness trip vital failure from an anti-TNF agent. Also, handiest a tiny bit better than one third (37%) dwell in clinical remission at 1 three hundred and sixty five days.
With that in thoughts, Buisson and his colleagues conducted the VENUS look to care for into consideration outcomes between ustekinumab and vedolizumab. These two biologic brokers are indicated for Crohn’s illness and performance diverse mechanisms of action when put next with anti-TNF brokers.
They assessed 312 adults with Crohn’s illness from two affected person cohorts in France. All participants failed prior remedy with at the least one anti-TNF agent, along with approximately 20% who experienced a predominant nonresponse.
The retrospective look incorporated 224 patients handled with ustekinumab and one other 88 with vedolizumab between July 2014 and Can also 2020. The 2 groups had been linked per a propensity diagnosis. Assorted medicines had been allowed at the physician’s discretion.
Nonresponders and Assorted Outcomes
“Vedolizumab patients had been more doubtless to be vital non-responders than ustekinumab patients,” Buisson stated. This team incorporated 6% of patients taking ustekinumab versus 14% of those taking vedolizumab.
In difference, in the case of secondary lack of response, “we didn’t look any [significant] difference between two groups,” he added.
The investigators outlined corticosteroid-free remission as a Crohn’s Disease Exercise Index decrease than 150 at week 54. They additionally assessed “deep remission” at 14 weeks, which used to be outlined as assembly corticosteroid-free remission and a fecal calprotectin of decrease than 100 microgram/gram.
They stumbled on that 26% of patients who obtained ustekinumab met the deep remission requirements versus 4% of those who obtained vedolizumab.
Buisson and colleagues additionally checked out time to drug escalation. A Kaplan Meier curve published that patients taking vedolizumab had been more doubtless to be escalated when put next with those taking ustekinumab (hazard ratio [HR], 1.35).
Furthermore, those handled with vedolizumab additionally featured a increased possibility for drug discontinuation due to the therapeutic failure (HR, 1.53).
Superior in Subgroup Analyses as Wisely
“No subgroups had been identified where vedolizumab used to be less advanced than ustekinumab,” Buisson stated. “In difference, ustekinumab used to be less advanced in five subgroups.”
The subgroups favoring ustekinumab incorporated those patients now not taking steroids at baseline; with no prior bowel resection; with a noncomplicated phenotype; with upper gastrointestinal involvement; and older than 35 years of age.
The retrospective look blueprint used to be a limitation. The lengthy notice-up and noteworthy sample size had been strengths.
The authors concluded that ustekinumab used to be less advanced to create early and lengthy-term efficacy than vedolizumab in patients with Crohn’s illness who previously failed to anti-TNF brokers.
“However, these files can occupy to be confirmed in a head-to-head randomized managed trial,” Buisson stated.
Digestive Disease Week (DDW) 2021 digital assembly. Abstract 26. Equipped Can also 21, 2021.
Buisson disclosed that he is a marketing consultant for Janssen and Takeda.
Damian McNamara is a crew journalist primarily primarily based in Miami. He covers a wide vary of scientific specialties, along with infectious illnesses, gastroenterology, and severe care. Apply Damian on Twitter: @MedReporter.
For more files, notice Medscape on Facebook, Twitter, Instagram, YouTube, and LinkedIn.